Top line growth accelerates as the new portfolio takes over
- Biogen is moving away from a shrinking MS base and toward Alzheimer's, rare disease, immunology, and eye disease products.
- In Q3 2026, the growth portfolio generated $1.3 billion and accounted for 63 percent of core pharmaceutical revenue.
- The Apellis acquisition is tracking ahead of schedule, contributing $243 million in the third quarter from SYFOVRE and EMPAVELI.
- SPINRAZA revenue surged 23 percent year over year, driven by the rapid adoption of its high-dose regimen.
- The bear case focuses on Medicare Part D pressures, legacy MS declines, and the heavy reliance on new drug launches.
A turnaround with proof instead of promises
Biogen used to be mostly a multiple sclerosis drug company. That old base is still large, but it is shrinking as TECFIDERA faces generics and TYSABRI faces biosimilar competition. The key change is that the newer products are now big enough to matter. In Q3 2026, total revenue grew 11 percent year over year, and the growth portfolio reached $1.3 billion.
The bull case got stronger after Biogen successfully integrated Apellis. SYFOVRE and EMPAVELI combined for $243 million in Q3 2026. The company is capturing deal synergies faster than expected, which helps offset near-term earnings dilution. Biogen also filed a record five INDs in 2026, aiming to build an early-stage pipeline of more than 20 programs to sustain growth long after the current launches mature.
LEQEMBI also moved forward. The FDA approved LEQEMBI IQLIK for at-home starting and maintenance doses. That matters because the older IV version needs infusion center time, which can slow patient starts. Easier use does not guarantee fast adoption, but it attacks one of the biggest barriers.
The bear case is still real. Tighter Medicare Part D formulary management is actively pressuring growth products like VUMERITY, which saw sales drop 11 percent in Q3 2026. The company now has a better growth path, but it still has to prove that the new portfolio can outrun the old decline and navigate a tougher reimbursement environment.
Replacing MS cash with new launches
Biogen makes money by selling prescription drugs, earning collaboration revenue, and collecting royalties. The old engine is MS. TYSABRI, TECFIDERA, AVONEX, and PLEGRIDY still bring in large sales, but most of that group is under pressure from generic competition.
The new model is launch-heavy. Biogen is pushing LEQEMBI, SKYCLARYS, ZURZUVAE, QALSODY, high-dose SPINRAZA, and now Apellis medicines. This takes sales spending, doctor education, patient support, and payer coverage. Biogen is using its cost cuts to help fund that shift, while heavily investing in R&D to target complex therapeutic areas like immunology.
Where it breaks is simple. If LEQEMBI starts stay slow, SYFOVRE loses share, or Medicare Part D changes force heavy discounts on key drugs, the company could be stuck between a fading legacy business and an expensive growth plan.
The drugs that decide the story
Legacy MS franchise
TECFIDERA, TYSABRI, AVONEX, and PLEGRIDY still matter, but the group is under pressure from generics, biosimilars, and patient shifts to newer options.
VUMERITY
Biogen counts VUMERITY as a growth product, though it faced an 11 percent revenue decline in Q3 2026 due to tighter Medicare Part D rules.
LEQEMBI
LEQEMBI is Biogen's Alzheimer's partnership with Eisai. The approval of LEQEMBI IQLIK for at-home doses could make treatment easier for doctors and patients.
SPINRAZA
SPINRAZA treats spinal muscular atrophy. The high-dose regimen is driving a major revenue resurgence and helping Biogen defend against oral rivals.
SKYCLARYS, QALSODY, and ZURZUVAE
These newer launches cover Friedreich's ataxia, SOD1-ALS, and postpartum depression. In Q3 2026, SKYCLARYS generated $178 million.
SYFOVRE and EMPAVELI
Biogen gained these drugs through Apellis. They generated $243 million in Q3 2026, providing immediate top-line growth.
Late-stage pipeline
Key pipeline bets include litifilimab for lupus, and felzartamab for kidney disease and microvascular inflammation.
Revenue mix transition
The mix reflects Biogen's broad revenue categories. Product revenue includes MS, rare disease, biosimilars, and the newly added Apellis medicines.
What could still go wrong
Apellis integration and SYFOVRE pressure
High impact · Medium oddsBiogen paid about $5.6 billion for Apellis, adding debt and near-term dilution. SYFOVRE sells into geographic atrophy, a highly competitive market. If Biogen cannot stabilize or grow SYFOVRE, the deal may add debt without enough earnings power.
LEQEMBI adoption stays slow
High impact · Medium oddsLEQEMBI has a huge possible market, but uptake has been slowed by health system limits. At-home LEQEMBI IQLIK helps with convenience, but patients still need screening and coverage. If doctors and payers move slowly, Alzheimer's revenue may not ramp fast enough.
Legacy MS decline outruns launches
High impact · High oddsBiogen's MS base is still large but fading. TECFIDERA and TYSABRI face generic and biosimilar competition. The company paused its own new MS drug because of market crowding.
Drug pricing and policy pressure
Medium impact · High oddsThe Medicare Part D redesign and tighter formulary management are actively suppressing revenues for products like VUMERITY. More pricing pressure or Medicare changes could weigh heavily on sales and margins.
In one breath
What is Biogen best known for?
Biogen is best known for neurology drugs, especially MS treatments and SPINRAZA for spinal muscular atrophy. It is now trying to become a broader company built around Alzheimer's, rare disease, immunology, and eye disease drugs.
Why did Biogen buy Apellis?
Biogen bought Apellis to add two marketed drugs right away: SYFOVRE and EMPAVELI. The deal is meant to make revenue growth less dependent on slow pipeline progress.
Why does LEQEMBI IQLIK matter?
LEQEMBI IQLIK lets patients receive Alzheimer's treatment with at-home injections instead of starting with IV infusions. That could lower the burden on patients, doctors, and infusion centers.
Is Biogen already growing again?
Yes. In Q3 2026, total revenue grew 11 percent year over year to $2.8 billion, driven by a $1.3 billion contribution from the growth products segment.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - General companies
Companies near Biogen Inc. in Finn's Drug Manufacturers - General industry ranking.

